GlassScriptPhysician profile
Guofang Wang
NPI 1326215690
$2,684.87
in general payments reported to CMS, 2019-2025
25 companies · $346 in 2025
The $346 reported for 2025 was more than what 86% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $93.82 · 2021: $422 · 2022: $165 · 2023: $474 · 2024: $427 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $981.19 | 2019-2025 | Vemlidy |
| Lilly USA, LLC | $470.21 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $376.34 | 2019-2025 | Linzess, Vraylar, Viberzi |
| Allergan, INC. | $128.46 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $75.72 | 2021-2022 | |
| Glaxosmithkline, LLC. | $75.01 | 2019-2022 | |
| Hologic Sales and Service, LLC | $69.93 | 2022-2025 | Aptima |
| Genentech USA, INC. | $55.23 | 2019 | |
| Redhill Biopharma INC. | $54.96 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $50.00 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $42.03 | 2023 | Prehevbrio |
| Amgen INC. | $36.54 | 2021-2025 | Evenity |
| Pfizer INC. | $31.08 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.20 | 2019 | |
| Exact Sciences Corporation | $27.58 | 2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meridian Bioscience INC. | $26.92 | 2024 | |
| Dexcom, INC. | $25.00 | 2025 | Dexcom G6 Transmitter |
| Aurinia Pharma U.S., INC. | $23.07 | 2023 | Lupkynis |
| Qiagen, LLC | $18.29 | 2025 | |
| Astellas Pharma US INC | $18.09 | 2023 | Myrbetriq |
| Dynavax Technologies Corporation | $17.40 | 2023 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $15.42 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $15.00 | 2025 | Voquezna |
| Vivus LLC | $12.41 | 2021 | |
| Acarix USA INC. | $8.79 | 2023 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guofang Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.